Covered recipient · General Payments record
ELIZABETH NAFZIGER
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2020–2024
$1,651.06
- Reported across 58 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $824.73 | 32 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $160.05 | 13 |
| LivaNova USA, Inc. | $159.40 | 2 |
| CATALYST PHARMACEUTICALS, INC. | $132.58 | 2 |
| UCB, Inc. | $66.14 | 2 |
| Teva Pharmaceuticals USA, Inc. | $43.41 | 1 |
| JAZZ PHARMACEUTICALS INC. | $34.25 | 1 |
| PFIZER INC. | $32.59 | 2 |
| EISAI INC. | $29.74 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $26.75 | 1 |
| Lilly USA, LLC | $24.07 | 1 |
| Lundbeck LLC | $23.24 | 1 |
| Genentech USA, Inc. | $21.57 | 1 |
| Alexion Pharmaceuticals, Inc. | $19.92 | 1 |
| SK Life Science, Inc. | $18.56 | 1 |
| TG THERAPEUTICS, INC. | $16.89 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $15.57 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (32)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $9.01 | 01/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105092733 | CMS |
| ABBVIE INC. | $25.72 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105092735 | CMS |
| ABBVIE INC. | $6.54 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105092737 | CMS |
| ABBVIE INC. | $6.25 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105092739 | CMS |
| ABBVIE INC. | $16.15 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105092741 | CMS |
| ABBVIE INC. | $7.83 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105092743 | CMS |
| ABBVIE INC. | $1.05 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105092745 | CMS |
| ABBVIE INC. | $17.02 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105092747 | CMS |
| ABBVIE INC. | $6.51 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105092749 | CMS |
| ABBVIE INC. | $18.76 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105092751 | CMS |
| ABBVIE INC. | $8.17 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105092753 | CMS |
| ABBVIE INC. | $17.62 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105092755 | CMS |
| ABBVIE INC. | $19.42 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105092757 | CMS |
| Alexion Pharmaceuticals, Inc. | $19.92 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093966989 | CMS |
| Boston Scientific Corporation | $26.75 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092513761 | CMS |
| CATALYST PHARMACEUTICALS, INC. | $122.41 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144453487 | CMS |
| CATALYST PHARMACEUTICALS, INC. | $10.17 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144453485 | CMS |
| Eisai Inc. | $29.74 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110743625 | CMS |
| Genentech USA, Inc. | $21.57 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133006499 | CMS |
| JAZZ PHARMACEUTICALS INC. | $34.25 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150227943 | CMS |
| Lilly USA, LLC | $24.07 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136171754 | CMS |
| LivaNova USA, Inc. | $14.52 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152801261 | CMS |
| LivaNova USA, Inc. | $144.88 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152801381 | CMS |
| Lundbeck LLC | $23.24 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145949232 | CMS |
| Novartis Pharmaceuticals Corporation | $15.57 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086984354 | CMS |
| PFIZER INC. | $16.53 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131289688 | CMS |
| PFIZER INC. | $16.06 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131497310 | CMS |
| SK Life Science, Inc. | $18.56 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154138704 | CMS |
| Teva Pharmaceuticals USA, Inc. | $43.41 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151714923 | CMS |
| TG Therapeutics, Inc. | $16.89 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136871489 | CMS |
| UCB, Inc. | $18.46 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143024982 | CMS |
| UCB, Inc. | $47.68 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143024984 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.